Science and Research

A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation (Mirati Krystal-12).

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

Study details
Study-ID: NCT04685135, 2020-003645-11
Study-ID: NCT04685135, 2020-003645-11
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: DZL, Externally - industry
Funding: DZL, Externally - industry
DZL Participating Sites: ARCN, UGMLC
DZL Participating Sites: ARCN, UGMLC
Start Date: 23.02.2021
Completion Date: 02.07.2026
Status: Active / not recruiting
Status: Active / not recruiting
DZL recruiting center, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.